Puma Biotech (PBYI) Tops Q1 EPS by 53c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Puma Biotech (PBYI) Tops Q1 EPS by 53c, Revenues Beat

Puma Biotech (PBYI) Licensing Partner CANbridge Pharmaceuticals Granted Marketing Approval in Mainland China for NERLYNX (neratinib)

May 7, 2020 8:36 AM EDT

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner CANbridge Pharmaceuticals, Inc. has received marketing approval of NERLYNX® (neratinib) in mainland China from the National Medical Products Administration (NMPA) of China. NERLYNX is indicated for the extended adjuvant treatment of adult patients with early stage human epidermal growth factor receptor 2 (HER2) positive breast cancer, to... More